ESLA Estrella Biopharma Inc

Top Stocks to watch tomorrow: $ESLA $XLAB $TANH $SAGT $SHFS XLAB: Good close of daily candle. Key support zone at 3.2 - 3.55. Next key level to test 5.1 - 5.5. Closed 4hours candle at 4.40 ESLA: Alerted at 0.55 yesterday. Currently at 0.73. Looking good on 4hours chart with updated support zone at 0.51 - 0.55. Next key level to test 0.84 - 0.88 SHFS: Alerted at 0.19 yesterday. It made a nice move to 0.54 afterwards. It now fell to key support zone of 0.25 - 0.29 on 4hours chart and may get a bounce off to test 0.37 - 0.4 zone again. TANH: Looking good on 4hours chart. Key support zone on 21 - 24. Next key level to test 36 - 39. Currently at 31 SAGT: Looking good on daily chart. key support zone at 0.56 - 0.6. Next key level to test 0.79 - 0.84. Currently at 0.7

Top Stocks to watch tomorrow : $ESLA $SDEV $SHFS $STAK $LHSW SHFS: Looking good on hourly chart. Key support zone at 0.1430 - 0.1510. Next key level to test 0.2470 - 0.2580. Currently at 0.19 STAK: Good close of 4hours candle. Key support zone at 1 - 1.10. Next key level to test 1.85 - 2.05. Currently at 1.48 SDEV: Looking good on 4hourly chart. 0.87 - 0.95 is acting as key support zone. Next key level to test 1.55 - 1.70. Currently at 1.20 ESLA: Getting up on 4hours chart. Key support zone at 0.39 - 0.43. Next key level to test 0.65 - 0.7. Currently at 0.55 LHSW: Looking good on 4hours chart. key support zone at 0.78 - 0.84. Next key level to test 1.22 - 1.35. Currently at 0.98

$ESLA ok looking for round 3 push. Past .84 it's wide open but not sure it'll close above.

$ESLA ASK to the 1.00 Breakout all the way to the 1.15's is super thin!!! Im on a mission

$ESLA this pos always announces he sold.. No respect to the OG pumping this from the .50's

$ESLA $4.00 Minimum PT Better load it before the sheeps come rushing in from above 1.00 to 1.58 range $$$$$

$ESLA Three white soldiers candlestick pattern. Strong volume. Bearish reversal on the P&F chart. Close at HOD. Dollar land next week perhaps.

Short sellers are ruining american small caps and driving companies into bankruptcy!! FMFC has barely 800 watchers on Stocktwits and has been shorted down to only 1.5 million market cap. You could literally buy the ENTIRE company! Webull data stating that FMFC has only 492k shares outstanding and 243k shares float. Watch FMFC here. Making a move 🚀 💎 👀 $ESLA $GPUS yy

$ESLA sitting in my pajamas drinking a Budweiser taking shots of Smirnoff trading this stock I love the weekdays more than the weekend now

$ESLA ok ready so up down rest of day closes up but not gonna run today sorry it’s Friday but Monday for sure we all know it

$ESLA looking at the charts theres too little resistance on the upside towards 1.2x this can easily run hard in these levels.

$ESLA started a position earlier this week at .48. Loaded today at .80. Bearish signal reversed today on the P&F chart. Looks to be heading up over $1 soon.

Brought $ESLA to you earlier today, highlighting Reports of Early Tolerability of Two EB103 Doses for T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL). Once again, you can get ahead of the game with one of our daily market research reports! 👔💼📉📈💎🙌.

$ESLA revealed its first patient tolerating two EB103 infusions with no treatment-related serious adverse events.

$ESLA and heere is your voice of good sense ;) stay away below .56 - there is a heavy distribution ongoing currently not the most attractive stock right now. will be interesting again after .65

$ESLA Cynthia Pussinen’s appointment as CEO and Board Chair represents an operational pivot for Estrella Immunopharma (ESLA). Until now, Estrella was operated essentially as an academic science project: Dr. Cheng Liu (now Chief Scientific Officer) discovered and licensed the ARTEMIS® platform through parent company Eureka Therapeutics, focusing on bench chemistry and small early trials. However, early-stage cell therapies cannot survive on good science alone—they require complex commercial manufacturing, institutional capital, and business development deals. Pussinen’s background directly addresses Estrella's three biggest vulnerabilities: capital starvation, cell therapy manufacturing/supply chain bottlenecks, and big pharma deal-making. 1. Solving the Manufacturing Bottleneck (The Spark & Pfizer DNA) Cell therapy is notoriously difficult to scale. Autologous T-cell therapies often fail not because the biology doesn't work, but because companies cannot manufacture and release lots reliably, cheaply, or quickly enough for clinical and commercial use. Spark Therapeutics (Roche Group): As Chief Technical Officer, Pussinen ran technical operations for LUXTURNA®—one of the earliest FDA-approved in-vivo gene therapies. She knows how to manage vector logistics, regulatory release assays, and cryogenic delivery. Pfizer & Actinium Leadership: Over 18 years at Pfizer, she led global supply chains, CDMO partner networks, and technical development. Impact on ESLA: With STARLIGHT-1 expanding across five clinical trial sites (Baylor Scott & White, OHSU, Univ. Hospitals Cleveland, Intermountain Health, and UC Davis), cell logistics become complex. Pussinen provides the operational expertise needed to ensure patients actually receive their multi-dose infusions on schedule without manufacturing failures. 2. The $35M, $55M, and $75M Capital Road Map Her compensation structure filed on Form 8-K reveals management's explicit playbook: [ PUSSINEN'S SEC CAPITAL ESCALATION LADDER ] │ ┌────────────────────────────────┼────────────────────────────────┐ ▼ ▼ ▼ [ THRESHOLD 1: >$35M ] [ THRESHOLD 2: >$55M ] [ THRESHOLD 3: >$75M ] • Salary jumps to $400,000 • Salary jumps to $450,000 • Salary jumps to $525,000 • Funds Phase 2 expansion • Funds multi-site registration • Commercial prep & global & clears going-concern debt and dual-target (EB104) IND scale-up validation The Reality: Estrella held less than $200k in cash reserves mid-year. To survive without wiping out existing shareholders, the company cannot simply sell tiny blocks of discounted penny stock to retail brokers. Sorbie Bornholm & VC Connections: Pussinen was Managing Director of Biotech Investments at Sorbie Bornholm. She understands institutional term sheets, PIPEs, and structured growth financing. What She Can Do: Her employment benchmarks indicate she took the job to execute large-scale capital formation. Reaching these thresholds would permanently eliminate Estrella’s going-concern warning and give the company years of runway. 3. Out-Licensing and M&A (The Ipsen Precedent) Estrella does not have the resources to run a global Phase 3 oncology trial independently. The ultimate goal for a micro-cap cell therapy company is to secure an out-licensing co-development deal or negotiate an outright acquisition by a major pharma player. Proven M&A Track Record: While President and CEO of Ipsen's U.S. subsidiaries, Pussinen led the strategic carve-out and divestiture of the hematology drug Obizur® and its manufacturing infrastructure to Baxter. Big Pharma Relationships: Having spent nearly two decades inside Pfizer's R&D Strategy and Portfolio division, she has personal relationships with corporate development executives across the industry. What She Can Do for ARTEMIS®: Because traditional CAR-Ts (Gilead's Yescarta, BMS's Breyanzi) suffer from severe cytokine release syndrome (CRS), Pussinen can market Estrella's low-toxicity ARTEMIS® platform directly to big pharma oncology scouts looking for safer next-generation cell receptors. 4. Leadership Division of Labor Prior to late October, Dr. Cheng Liu was trying to serve simultaneously as CEO, Chairman, chief fundraiser, clinical coordinator, and lead scientist. By bringing in Pussinen as CEO and Board Chair, the leadership team splits into complementary roles: Dr. Cheng Liu (CSO): Focuses strictly on cellular design, optimizing the ARTEMIS® construct, and progressing EB104 (the CD19/CD22 dual-target asset) through preclinical stages. Cynthia Pussinen (CEO & Chair): Focuses on clinical trial site throughput, Wall Street capital markets, non-dilutive licensing deals, and strategic pharma partnerships. What Success Under Pussinen Means for Shareholders If Pussinen executes the playbook she has used throughout her career: Removes the Insolvency Discount: Securing the first >$35M financing tranche (either through a strategic pharmaceutical partnership or an institutional investment) eliminates bankruptcy risk. Restores Nasdaq Standing: Re-rating the company’s enterprise value to reflect a funded Phase 2 asset pushes the stock securely above the $1.00 minimum bid requirement. Sets Up an Exit Event: Building clinical proof-of-concept across five active sites positions Estrella for an acquisition or licensing buyout by a major oncology leader.

$ESLA nice move today on some volume. My only green in a sea of red. Just holding patiently through the extreme ups and downs since my purchase at .54 hoping that she'd recover again like i thought she should. What a nice surprise. Problem is, she still has some really low volume days where it's easy to sell and manipulate. Though those days are getting fewer.

Massive 3000% call on OMH dude! Just turned my month green. Up 9k$ profit Give that a Follow <-- Finds the runners early 🔥💯 Nice accumulation on $ESLA $LNKS here

$ESLA $CODX $TVRD And another on the list... essentially the exact same pattern. Ironically, seems like TVRD has been (please forgive me) flushed down least of the three 🤦‍♂️🤦‍♂️🤦‍♂️

🚀 5m ORB Alert: $ESLA • Breakout Level: $1.10 • Quality Score: 66/100 • Volume Surge: 1.5x ⏰ Feed delayed 5 mins! Get live alerts + profit targets at the link in my bio!